Takeda
650 East Kendall Street
Cambridge
MA
02421
United States
Website: https://www.takeda.com/
Email: info@takeda.com
About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com.
Stock Symbol: TAK
Science is the foundation for everything we do at Takeda. We connect to our 240- year history and our strong values through our pursuit of life-transforming science where we embrace a culture of collaboration, pursue modalities based on validated targets, evaluate real-world impact and generate data that may enable accelerated development and regulatory pathways.
1525 articles about Takeda
-
Takeda Pharmaceutical Co. Ltd. to Delay European Application for Key Drug
6/5/2009
-
PPD, Inc. Announces Takeda Pharmaceutical Co. Ltd. to Conduct Additional Study for Alogliptin MAA in the EU
6/4/2009
-
Sucampo Pharmaceuticals, Inc. Board of Directors Issues Statement Regarding Sales Performance by Takeda Pharmaceuticals North America, Inc. for AMITIZA
5/29/2009
-
Takeda Pharmaceutical Co. Ltd. to Acquire IDM Pharma, Inc. for $75 Million, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
5/18/2009
-
FDA Approves Takeda Pharmaceutical Co. Ltd.'s ACTOplus met(R) XR Tablets for the Treatment of Type 2 Diabetes
5/14/2009
-
Takeda Pharmaceutical Co. Ltd. to Take Back Actos Rights from Eli Lilly and Company
4/8/2009
-
Takeda Pharmaceutical Co. Ltd. Cancer Drug Slows Tumor Growth in Mice
4/8/2009
-
Takeda Pharmaceutical Co. Ltd. to Create Global Centers of Excellence; Shinji Honda Named New CEO, Expands its Own Sales and Marketing Operations in Europe
3/31/2009
-
Takeda Pharmaceutical Co. Ltd. Shares Plunge on Drug Delay Worries
3/9/2009
-
Takeda Pharmaceutical Co. Ltd. Says FDA Needs More Data on Key Diabetes Drug
3/6/2009
-
Takeda Pharmaceuticals North America, Inc. Release: KAPIDEX(TM) (dexlansoprazole) Delayed Release Capsules Now Available for the Treatment of GERD
2/24/2009
-
Teijin Pharma and Takeda Pharmaceutical Co. Ltd. Announce ULORIC Receives FDA Approval for the Chronic Management of Hyperuricemia in Patients with Gout
2/17/2009
-
Japan's Takeda Pharmaceutical Co. Ltd. (JOBS), U.S. XOMA (US) LLC to Expand Ties; Takeda Would Pay $29 Million
2/10/2009
-
FDA Approves Takeda Pharmaceutical Co. Ltd.'s KAPIDEX(TM) (Dexlansoprazole) Delayed Release Capsules for the Treatment of GERD
2/2/2009
-
Takeda Pharmaceutical Co. Ltd. Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
1/22/2009
-
Review of Takeda Pharmaceutical Co. Ltd.'s Febuxostat New Drug Application Continues Past PDUFA Date
1/20/2009
-
CellCentric Ltd. and Takeda Pharmaceutical Co. Ltd. Collaborate on Epigenetic Programme
1/6/2009
-
Takeda Pharmaceutical Co. Ltd. Says US FDA to Respond on Diabetes Drug by June
12/29/2008
-
Takeda Pharmaceutical Co. Ltd. Starts Japan Phase III Trials for Obesity Drug
12/22/2008
-
Cell Genesys, Inc. and Takeda Pharmaceutical Co. Ltd. (JOBS) Announce Termination of Collaboration Agreement for GVAX Immunotherapy for Prostate Cancer
12/3/2008